Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.49 |
| ▸ | HTR3B | O95264 | 4/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31651688 | 0.87 | LMNA (0.51) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL19709597 | 0.81 | ADRB1 (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL30952462 | 0.81 | ADRB1 (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL17893625 | 0.79 | ALDH1A1 (0.44) | LMNAMAPTSLC6A3 | |
| SCHEMBL11297059 | 0.79 | LMNA (0.50) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8116406 | 0.79 | LMNA (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8191985 | 0.79 | HTR1A (0.46) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL23102235 | 0.78 | ALDH1A1 (0.38) | DRD2HTR6MAPTHTR2ASLC6A3 | |
| SCHEMBL21361445 | 0.78 | MAPT (0.42) | DRD2LMNAMAPT | |
| Hydrochloric Acid SCHEMBL15937978 | 0.78 | LMNA (0.48) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| CN-112262129-A | Triazacyclododecane sulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-3765447-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | HTR3A 4144/4885HTR3E 3724/4885HTR3B 4151/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HTR3A 4091/4885HTR3E 3609/4885HTR3B 4053/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | HTR3A 2667/4885HTR3E 1975/4885HTR3B 3580/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HTR3A 3869/4885HTR3E 3388/4885HTR3B 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.